Research
Hormonal
Once-weekly semaglutide 2.4 mg produces significantly greater weight loss than once-daily liraglutide 3.0 mg in patients with obesity, based on indirect comparisons of randomized controlled trials.
If you are treating obesity with GLP-1 agonists, semaglutide (2.4 mg weekly) is likely to produce roughly twice the weight loss of liraglutide (3.0 mg daily). This benefit comes with a once-weekly injection schedule, which may improve adherence compared to daily injections, though gastrointestinal side effects are common with both.
ModerateSupportsMEDIUM confidence
In clinical trials of OW semaglutide, this drug was consistently associated with greater weight loss than in trials of OD liraglutide. Thus, placebo-corrected percentage weight reduction was -10.3 to -12.4% and -5.4% with OW semaglutide and OD liraglutide, respectively.
Why this rating
Based on indirect comparisons of separate trials rather than head-to-head trials.
Source
Semaglutide versus liraglutide for treatment of obesity
Nasser Mikhail · 2021
DOI 10.32474/ado.2021.03.000162
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Both semaglutide and liraglutide cause gastrointestinal adverse effects (nausea, vomiting, diarrhea) which are the most common reason for drug discontinuation.Good
- Semaglutide and liraglutide have similar anti-hyperglycemic efficacy, with no consistent significant difference in HbA1c reduction between the two drugs.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →